Evidence map›Paper›PMID 36157476›Full record

ArticleGenes & diseases2022

Targeting BMI1 mitigates chemoresistance in ovarian cancer.

Anindya Dey, Shailendra Kumar Dhar Dwivedi, Lin Wang, Md Nazir Hossen, Fiifi Neizer-Ashun, Magdalena Bieniasz, Priyabrata Mukherjee, John D Baird, Marla Weetall, Resham Bhattacharya

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Anindya DeyDepartment of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Shailendra Kumar Dhar DwivediDepartment of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Lin WangDepartment of Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Md Nazir HossenDepartment of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Fiifi Neizer-AshunDepartment of Cell Biology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
Magdalena BieniaszDepartment of Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Priyabrata MukherjeeDepartment of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
John D BairdPTC Therapeutics, Inc, South Plainfield, NJ 07080, USA.
Marla WeetallPTC Therapeutics, Inc, South Plainfield, NJ 07080, USA.
Resham BhattacharyaDepartment of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA.
University of Oklahoma Health Sciences Center · USOklahoma Medical Research Foundation · USPTC Therapeutics (United States) · USCalifornia Northstate University · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michael S. Businelle · 2018 to 2026
$27.1M
NCI NIH HHS P30 CA225520
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36157476
PMCPMC9485277
OpenAlexW4220994095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.